Limits...
Expression of DLK1 Gene in the Bone Marrow Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significance.

Yue LZ, Fu R, Wang HQ, Li LJ, Ruan EB, Wang GJ, Qu W, Liang Y, Guan J, Wu YH, Liu H, Song J, Wang XM, Xing LM, Shao ZH - Cancer Biol Med (2012)

Bottom Line: Moreover, DLK1 mRNA expression was significantly increased as MDS progressed (P<0.05).Patients with abnormal karyotypes exhibited significantly higher expression of DLK1 mRNA (0.9007±0.4334) than those with normal karyotypes (0.6411±0.2630) (P<0.05).Subsequently, patients with highly expressed DLK1 (≥0.8) presented significantly higher malignant clone burden (0.4134±0.3999) than those with lower DLK1 expression (<0.8),(0.1517±0.3109), (P<0.05).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China.

ABSTRACT

Objective: This study aims to investigate the expression of delta-like 1 (DLK1) gene in the bone marrow cells of patients with myelodysplastic syndromes (MDS) and to explore its molecular characteristics for the early diagnosis of MDS.

Methods: The expression of DLK1 mRNA in the bone marrow cells of cases with MDS, acute myeloid leukemia (AML), and normal control groups were measured by real-time polymerase chain reaction and were analyzed for clinical significance.

Results: Significantly higher expression of DLK1 mRNA was observed in the bone marrow cells of MDS patients (0.7342±0.3652) compared with the normal control group (0.4801±0.1759) (P<0.05). The expression of DLK1 mRNA had a positive correlation with the proportion of bone marrow blasts (r=0.467, P<0.05). Moreover, DLK1 mRNA expression was significantly increased as MDS progressed (P<0.05). Patients with abnormal karyotypes exhibited significantly higher expression of DLK1 mRNA (0.9007±0.4334) than those with normal karyotypes (0.6411±0.2630) (P<0.05). Subsequently, patients with highly expressed DLK1 (≥0.8) presented significantly higher malignant clone burden (0.4134±0.3999) than those with lower DLK1 expression (<0.8),(0.1517±0.3109), (P<0.05).

Conclusions: The DLK1 gene was highly expressed in MDS patients, and was increased as MDS progressed. The expression of DLK1 mRNA was positively correlated with the proportion of the bone marrow blasts. A high expression of DLK1 gene suggested a higher malignant clone burden of MDS.

No MeSH data available.


Related in: MedlinePlus

Expression of DLK1 gene in MDS and normal control groups. 1: Normal control group; 2: MDS patients
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3643669&req=5

f1: Expression of DLK1 gene in MDS and normal control groups. 1: Normal control group; 2: MDS patients

Mentions: The expression of DLK1 mRNA in the bone marrow cells of MDS patients was significantly higher than that of the normal control group (P<0.05) (Figure 1). The expression of DLK1 gene in AML patients was higher than that of the normal control group, but lower than that of MDS patients, with no statistical significances (P>0.05). Furthermore, the level of DLK1 expression in the 6 untreated or relapsed AML patients was 0.6737±0.2748, which was lower than the MDS group but higher than the control group, with no significant differences (P>0.05, Table 1).


Expression of DLK1 Gene in the Bone Marrow Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significance.

Yue LZ, Fu R, Wang HQ, Li LJ, Ruan EB, Wang GJ, Qu W, Liang Y, Guan J, Wu YH, Liu H, Song J, Wang XM, Xing LM, Shao ZH - Cancer Biol Med (2012)

Expression of DLK1 gene in MDS and normal control groups. 1: Normal control group; 2: MDS patients
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3643669&req=5

f1: Expression of DLK1 gene in MDS and normal control groups. 1: Normal control group; 2: MDS patients
Mentions: The expression of DLK1 mRNA in the bone marrow cells of MDS patients was significantly higher than that of the normal control group (P<0.05) (Figure 1). The expression of DLK1 gene in AML patients was higher than that of the normal control group, but lower than that of MDS patients, with no statistical significances (P>0.05). Furthermore, the level of DLK1 expression in the 6 untreated or relapsed AML patients was 0.6737±0.2748, which was lower than the MDS group but higher than the control group, with no significant differences (P>0.05, Table 1).

Bottom Line: Moreover, DLK1 mRNA expression was significantly increased as MDS progressed (P<0.05).Patients with abnormal karyotypes exhibited significantly higher expression of DLK1 mRNA (0.9007±0.4334) than those with normal karyotypes (0.6411±0.2630) (P<0.05).Subsequently, patients with highly expressed DLK1 (≥0.8) presented significantly higher malignant clone burden (0.4134±0.3999) than those with lower DLK1 expression (<0.8),(0.1517±0.3109), (P<0.05).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology, General Hospital of Tianjin Medical University, Tianjin 300052, China.

ABSTRACT

Objective: This study aims to investigate the expression of delta-like 1 (DLK1) gene in the bone marrow cells of patients with myelodysplastic syndromes (MDS) and to explore its molecular characteristics for the early diagnosis of MDS.

Methods: The expression of DLK1 mRNA in the bone marrow cells of cases with MDS, acute myeloid leukemia (AML), and normal control groups were measured by real-time polymerase chain reaction and were analyzed for clinical significance.

Results: Significantly higher expression of DLK1 mRNA was observed in the bone marrow cells of MDS patients (0.7342±0.3652) compared with the normal control group (0.4801±0.1759) (P<0.05). The expression of DLK1 mRNA had a positive correlation with the proportion of bone marrow blasts (r=0.467, P<0.05). Moreover, DLK1 mRNA expression was significantly increased as MDS progressed (P<0.05). Patients with abnormal karyotypes exhibited significantly higher expression of DLK1 mRNA (0.9007±0.4334) than those with normal karyotypes (0.6411±0.2630) (P<0.05). Subsequently, patients with highly expressed DLK1 (≥0.8) presented significantly higher malignant clone burden (0.4134±0.3999) than those with lower DLK1 expression (<0.8),(0.1517±0.3109), (P<0.05).

Conclusions: The DLK1 gene was highly expressed in MDS patients, and was increased as MDS progressed. The expression of DLK1 mRNA was positively correlated with the proportion of the bone marrow blasts. A high expression of DLK1 gene suggested a higher malignant clone burden of MDS.

No MeSH data available.


Related in: MedlinePlus